Efficacy of combination therapy
TUMOR PROGRESSION
A total of 9 patients (45.0%) in the RFA combined with anti‐PD‐1 group and 16 patients (80.0%) in the RFA group showed tumor progression. As shown in Figure The RFS with combination therapy and RFA alone. RFA, radiofrequency ablation; RFS, recurrence‐free survival.The RFS at 6, 12, and 18 months in the RFA combined with anti‐PD‐1 and RFA groups.Abbreviations: anti‐PD‐1, toripalimab; RFA, radiofrequency ablation; RFS, recurrence‐free survival.